London-based technology venture investor with VCT and institutional strategies spanning European pre-seed software and AI, pre-seed/seed deeptech and life sciences, and growth opportunities. Official institutional page reports GBP 1.2 billion manager AUM (undated, accessed 2026-10-06), not a single fund. Current legal footer identifies AlbionVC LLP; historical Albion Capital manager names are retained in sourced research.
Founded —
Type Venture capital 3 UCL Technology Fund 2 2020-08-03 2020-08-03 — First close announced toward GBP 100m target; actual first-close and final-close amounts unverified. Amount intentionally unset; manager AlbionVC with UCL Business.
UCL Technology Fund 1 2016-01-18 2016-01-18 £50M Announced GBP 50m launch investment capital; Albion-managed UCL research commercialisation vehicle.
Growth Opportunities Fund II — — Official current institutional page states investing from Fund II. Size, vintage and closing date undisclosed.
SHOW MORE
$7M $5M – $10M Cambridge, United Kingdom $7M $5M – $10M London $7M $5M – $10M London $7M $5M – $10M London $7M $5M – $10M London $7M $5M – $10M United Kingdom $7M $5M – $10M United Kingdom · London $7M $5M – $10M United Kingdom · London $1M $250K – $3M London $1M $100K – $5M London $50K $25K – $100K London — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – —
SHOW MORE
$— 2026-07-10 Resolyst AlbionVC $— 2026-02-25 Kinfolk AlbionVC $75M 2026-02-10 TEM Lightspeed , Schroders Capital , Voyager Ventures , Revent , Atomico , Hitachi Ventures , AlbionVC $75M 2026-02-09 Tem Energy Lightspeed , Voyager Ventures , Revent , Atomico , AlbionVC , Hitachi Ventures $75M 2026-02-09 TEM Lightspeed , AlbionVC $24M 2026-02-04 Bound AlbionVC , Notion Capital $— 2026-01-28 Evaro AlbionVC $12M 2026 Flok Y Combinator , AlbionVC , Form Ventures , Mercia Asset Management $— 2025-11-13 Scripta Therapeutics AlbionVC $— 2025-10-01 Mondra AlbionVC , Planet A Ventures $34M 2025-09-02 Phasecraft Plural , AlbionVC , Playground Global , Ian Hogarth , Peter Barrett $— 2025-06-11 OpenTrade Notion Capital , AlbionVC $30M 2025-06-03 Treefera Notion Capital , AlbionVC , Triple Point Ventures , Paul Lehair , Patrick Norris $— 2025-06-03 Labrys Plural , AlbionVC , Expeditions , Project A Ventures $25M 2025-04-09 TransFICC AlbionVC , Cat McDonald $17M 2025-02-05 IONATE AlbionVC , IQ Capital , David Grimm $— 2025 EpilepsyGTx AlbionVC $— 2024-09-11 TEM Atomico , AlbionVC $6M 2024-08-15 Trumpet AlbionVC , Triple Point Ventures , Paul Lehair £10M 2024-03-27 Oriole Networks XTX Ventures , David Grimm , AlbionVC $— 2024-03-04 Gridcog AlbionVC $— 2024 Senya Tx AlbionVC $— 2023-11-02 Accelex AlbionVC $13M 2023-10-10 Kennek HV Capital , Founders Fund , Plug and Play Tech Center , DFF Ventures , ff Venture Capital , Syndicate One , AlbionVC , Barbod Namini $— 2023-08-16 Phasecraft Playground Global , AlbionVC $— 2023-07-06 Umed AlbionVC $— 2023-04-03 Quantexa AlbionVC $— 2023-03-16 Seldon AlbionVC , Amadeus Capital Partners $— 2023 Seldon AlbionVC , Amadeus Capital Partners $— 2022-11-08 5mins AlbionVC , Blue Lion Global , Portfolio Ventures $10M 2022-10-18 OutThink AlbionVC , Cat McDonald $7M 2022-08-30 Neurofenix AlbionVC $12M 2022-08-22 PeakData AlbionVC , Christoph Ruedig $— 2022-06-30 Black Swan Data AlbionVC $62M 2022-06-28 Speechmatics AlbionVC , IQ Capital $17M 2022-03-30 TransFICC AlbionVC , Cat McDonald $— 2022-02-21 Perchpeek AlbionVC $— 2022 RegGenome AlbionVC $— 2022 OpenDialog AlbionVC $— 2022 Gravitee AlbionVC $— 2022 Bramble Energy AlbionVC $5M 2021-12-22 Brytlyt AlbionVC , Amadeus Capital Partners , Cat McDonald $— 2021-11-29 Quell Therapeutics AlbionVC $— 2021-07-12 Quantexa AlbionVC $— 2021-05-17 Healios AlbionVC $26M 2021-05-11 Panaseer AlbionVC , Notion Capital $— 2021 Solidatus AlbionVC $— 2021 Quell Therapeutics AlbionVC $— 2021 5mins AlbionVC $3M 2020-11-18 Nozzle.ai AlbionVC , David Grimm $21M 2020-01-14 Oviva AlbionVC , Earlybird Venture Capital , Partech $— 2020 uMotif AlbionVC $— 2020 Seldon AlbionVC $— 2020 Credit Kudos AlbionVC $6M 2020 Concirrus AlbionVC , IQ Capital $— 2020 Bramble Energy AlbionVC $— 2019-10-21 Speechmatics AlbionVC , IQ Capital $— 2019-09-16 Echopoint Medical AlbionVC $— 2019-09-04 Elliptic AlbionVC $12M 2019-08-29 Koru Kids Founders Fund , 7percent Ventures , Atomico , Samos Investments , Forward Partners , AlbionVC $— 2019 Senya Tx AlbionVC $— 2018-12-18 Egress AlbionVC $— 2018-08 Concirrus AlbionVC $— 2017 Third Space Learning AlbionVC $— 2014-02 Egress AlbionVC $— Unknown date Toqio AlbionVC $— Unknown date Scripta AlbionVC $— Unknown date Proveca AlbionVC $— Unknown date Oxford Immunotec AlbionVC $— Unknown date Ophelos AlbionVC $— Unknown date Ophelos AlbionVC $— Unknown date Instinct Digital AlbionVC $— Unknown date Gravitee.io AlbionVC $— Unknown date Gravitee.io AlbionVC $— Unknown date GeoSurge AlbionVC $— Unknown date Flok Health AlbionVC $— Unknown date Antenova AlbionVC $— Unknown date Ambro AlbionVC $— Unknown date Agio Ratings AlbionVC $2M Unknown date Humanloop Y Combinator , Index Ventures , AlbionVC $75M Unknown date Tem Energy Lightspeed , Schroders Capital , Voyager Ventures , Atomico , AlbionVC , Hitachi Ventures $— 2025-11-04 Fit Collective AlbionVC $4M 2025-08-18 Innerworks Founders Fund , Digital Currency Group , AlbionVC , Cat McDonald $22M 2024-10-21 Oriole Plural , AlbionVC $— 2023 Latent Technology AlbionVC , Root Ventures $— 2022-11-15 WeGift AlbionVC $— 2020-11-25 WeGift AlbionVC $— 2018 Clear Review AlbionVC $8M 2016-02-02 Grapeshot AlbionVC , IQ Capital $— Unknown date Regulatory Genome AlbionVC $— Unknown date Outthink Io AlbionVC
SHOW MORE
team@apexlogos.ai · 11 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities.
Capital, funds and current fundraising
| Capital measure / vehicle | Amount and status | Date and supporting source | Interpretation |
|---|---|---|---|
| AlbionVC manager AUM | **£1.2bn**, current website headline | [Institutional investors](https://albion.vc/institutional-investors/ ), undated, accessed 2026-10-06 | Manager assets, not an individual fund or available investment budget. No valuation/as-of date supplied. |
| Albion VCT assets | Website presents **780m AUM** in UK VCT context | [VCT overview](https://albion.vc/vct/ ), undated, accessed 2026-10-06 | VCT segment metric; the rendered headline omits the currency symbol. The UK context implies sterling, but review underlying reports before storing exact dated AUM. Another official Enterprise page still says over £680m, showing stale cross-page metrics. |
| Albion VCT **2026/27** top-up offers | **£40m base target plus possible £20m over-allotment**; **£10.3m raised as at 6 October 2026**, still open | [Official offers page](https://albion.vc/vct/offers/ ), explicitly dated 2026-10-06 | Latest-known live fundraising checked. Aggregate additions to three existing listed trusts, not a new standalone £60m VC fund or final close. Base allocations: Enterprise £15m, Crown £10m, Technology & General £15m; extra £10m each available for Enterprise/Technology & General subject to approval. |
| Albion VCT **2025/26** top-up offers | £60m base target plus £30m over-allotment; announced first-day receipts £11m | [Intention announcement](https://albion.vc/spotlight/news/intention-to-launch-albion-vct-top-up-offers-2/ ), 2025-08-27; [first-day update](https://albion.vc/spotlight/news/albions-vct-top-up-offer-raises-11mn-in-first-day/ ), 2025-11-05 | Historical offer, distinct from current 2026/27 campaign. |
| Albion Crown portion of 2025/26 offers | **£30m raised**; offer fully subscribed/closed 2026-03-16 | [Crown interim report](https://albion.capital/wp-content/uploads/2026/03/CRWN31Dec2025.pdf ), report to 2025-12-31 with later offer update | Crown's amount only. Do not multiply or assume an aggregate £90m final close without each trust's confirmation. |
| UCL Technology Fund 1 | **£50m** announced launch investment capital | [UCL launch notice](https://www.ucl.ac.uk/news/headlines/2016/jan/ucl-raises-ps50m-spin-new-companies-out-research ), 2016-01-18 | Research commercialisation vehicle, not all Albion assets. |
| UCL Technology Fund 2 | First close toward a **£100m target**; actual first-close amount not specified | [UCL Fund 2 announcement](https://www.ucl.ac.uk/news/2020/aug/ucl-technology-fund-announces-first-close-ps100m-fund-2 ), 2020-08-03 | Managed by AlbionVC with UCL Business. **£100m is a target**, not verified final-close capital. |
| UCL Technology Funds 1 + 2 combined | **Over £125m raised** | [UCL Ventures funding/support](https://www.uclventures.com/funding-support ), undated, accessed 2026-10-06 | Combined historical fundraising, not Fund 2 size. A 2025 prospectus stated £122m combined, likely a timing/scope difference requiring review. |
| Growth Opportunities Fund II | Current official page says investing from Fund II | [Institutional investors](https://albion.vc/institutional-investors/ ), undated, accessed 2026-10-06 | Size, vintage and final-close date not found in sources checked. Likewise no verified named current pre-seed/Frontiers fund close amount found. |
The [September 7, 2026 IFA Magazine headline](https://ifamagazine.com/albionvc-launches-60m-vct-top-up-offer-to-back-uks-next-tech-generation/ ) calls the new offer £60m. The official live page clarifies £40m base plus £20m optional capacity. The article was search-index accessible but direct opening returned 403; prefer the official split. The historical [2025/26 prospectus](https://albion.capital/wp-content/uploads/2025/10/Albion-VCTs-2025-2026-Securities-Note-23102025.pdf ), dated 2025-10-23, also reports over £700m VCT assets at 2025-06-30 and £122m combined UCL funds. These figures have different scopes and dates and should not replace one another without context.
Funds recorded in Adex after this review:
| Fund | Disclosed amount | Announcement / filing date |
| --- | --- | --- |
| Growth Opportunities Fund II | Undisclosed / unverified | Unknown |
| UCL Technology Fund 1 | GBP 50000000 | 2016-01-18 |
| UCL Technology Fund 2 | Undisclosed / unverified | 2020-08-03 | SHOW MORE
team@apexlogos.ai · 12 hours ago
Match research 2026-10-06 / AlbionVC / sha256:5de97f2c364fd0d6f74387944f7018ae437d57f124427069b83d084f231bf849 / part 3 of 3
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
7. Signal duplicate spellings, sparse rendering and partner ranges limit confidence; Goldi, aggregators and the original baseline were discovery leads, not independent proof. Official company/manager announcements establish attribution but are interested-party sources; no audited exhaustive portfolio reconciliation is implied.
This file records evidence for later review only. Adex/database writes, MCP Patch and commits were not performed. SHOW MORE
team@apexlogos.ai · 12 hours ago
Match research 2026-10-06 / AlbionVC / sha256:5de97f2c364fd0d6f74387944f7018ae437d57f124427069b83d084f231bf849 / part 2 of 3
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
All amounts below are **total financing rounds**, not Albion's individual check. Classification uses specific underlying technology; ordinary SaaS entries in the snapshot are not automatically deeptech.
| Company | Technology rationale and verified attribution | Round / date / source |
|---|---|---|
| **IONATE** | Smart-grid hardware and control software, including Hybrid Intelligent Transformer and Aurora grid platform. AlbionVC explicitly **led** the financing; direct manager-name attribution. | **$17m Series A**, **2025-02-05**. [Albion announcement](https://albion.vc/spotlight/news/ionate-raises-17m-series-a-to-modernise-power-systems-as-demand-intensifies-globally/ ). Individual Albion amount and investing vehicle not disclosed. |
| **Oriole Networks** | Photonic networking, proprietary network-interface cards/transceivers and scheduling to improve AI/data-centre efficiency; substantial hardware/computer-science innovation. Albion explicitly says it participated. | **£10m seed**, **2024-03-27**. [Why Albion invested](https://albion.vc/spotlight/perspectives/why-we-invested-in-oriole-networks/ ). The article does not resolve the precise legal investing vehicle. Snapshot's later 2024 Series A entry is distinct and should not overwrite this seed evidence. |
| **Phasecraft** | Hardware-agnostic, efficient quantum algorithms for imperfect contemporary quantum computers; quantum computing is a clear deeptech fit. University announcement names **AlbionVC as an existing participating investor**; co-leads were Plural, Playground Global and Novo Holdings' Quantum Fund. | **$34m Series B**, **2025-09-02**. [UCL Ventures announcement](https://www.uclventures.com/spinout-portfolio-news/2026/quantum-algorithm-developer-phasecraft-raises-34-million-series-b ). Page path contains `/2026/` but article's displayed date is September 2, 2025. No Albion check amount disclosed. |
| **NeuroHarmonics** | Non-invasive focused ultrasound targeting deep-brain structures; both direct neurotechnology and deeptech. Albion's portfolio lists it and the investee names UCL Technology Fund as a backer. | See dedicated neurotech evidence below. Financing amount/date not publicly verified in primary sources checked. |
Additional current official [deeptech hub](https://albion.vc/deeptech-hub/ ) lists **Intrinsic** (silicon non-volatile memory), **Stanhope AI** (active inference), and other technical companies (undated, accessed 2026-10-06). An [Albion article dated 2022-02-22](https://albion.vc/spotlight/perspectives/a-computing-impasse-the-investments-we-make-now-will-define-our-future/ ) specifically attributes Intrinsic's silicon-oxide memristor investment to **UCL Technology Fund**. These support broader portfolio leads; precise rounds/checks were not resolved here.
## Named neurotechnology and adjacent investments
### Direct neurotechnology: NeuroHarmonics
**Verified fund-manager exposure, with explicit vehicle distinction.** Albion's [official portfolio](https://albion.vc/companies/ ) lists Neuroharmonics as early-stage deeptech, describing non-invasive ultrasound for the brain (undated, accessed 2026-10-06). The investee's [first-patient trial announcement](https://neuroharmonics.com/news/first-patient-trial-essential-tremor/ ), **2026-09-08**, names **UCL Technology Fund**, Speedinvest, Fusion Fund and Jumpspace Ventures as backers. Together with UCL's confirmation that AlbionVC manages that fund, this supports Albion-managed investment, rather than a partner's personal or prior-employer deal.
The technology modulates deep-brain neural activity with non-invasive ultrasound, making this direct neurotechnology rather than a mental-health software inference. The announced essential-tremor trial received MHRA/ethics clearance and **£1.2m Innovate UK support**; that amount is **grant/programme support, not an Albion equity check or total equity round**. The [company's development history](https://neuroharmonics.com/news/our-journey/ ), **2025-05-09**, describes transcranial ultrasound system development and early human validation. The [studies page](https://neuroharmonics.com/studies/ ) explicitly describes devices as investigational and not approved for clinical use (undated, accessed 2026-10-06).
Equity round size, exact initial investment date, Albion check and specific fund vintage remain unverified. A third-party shareholder report suggests a US-parent restructuring, but it is insufficient to infer a realised exit; company/fund backing still appears in current primary sources. Do not equate absence from the saved Adex investment list with lack of exposure.
### Neurorehabilitation: Neurofenix
**Confirmed AlbionVC investment; classify separately from neural sensing/stimulation.** [InHealth Ventures' co-investor announcement](https://www.inhealth.vc/portfolio/our-investment-in-neurofenix/ ) directly confirms investment alongside Albion VC in a **$7m Series A** (undated, accessed 2026-10-06). [NeuroNews International](https://neuronewsinternational.com/neurofenix-completes-us7-million-series-a-funding-for-digital-stroke-and-brain-injury-recovery-platform/ ), **2022-09-05**, reports AlbionVC led it, with HTH, InHealth Ventures and existing investors. The saved Adex date is 2022-08-30; reputable coverage places the announcement in late August/early September, so preserve that distinction.
NeuroBall uses motion sensors and app-based games for arm/hand rehabilitation after stroke or brain injury. This is **device-enabled neurological rehabilitation**, not evidence of a BCI, recording neural signals or directly stimulating neurons. The current Albion portfolio marks Neurofenix **Exited**, but an exit date/acquirer was not verified. No individual Albion investment amount disclosed.
### Adjacent neuroscience biotechnology: EpilepsyGTx
**Verified UCL Technology Fund 2 historical seed exposure; 2025 Series A Albion participation is not established by the checked primary announcement.** [UCL News](https://www.ucl.ac.uk/news/2025/dec/ucl-spinout-epilepsygtx-raises-33-million-new-epilepsy-treatments ), **2025-12-12**, reports **$33m Series A** provided by XGEN Venture, British Business Bank and an unnamed global biopharmaceutical company. It also confirms **$10m seed funding in 2024 from UCL Technology Fund 2**.
Its EPY201 gene therapy is delivered locally to the seizure focus for refractory epilepsy. This is neuroscience gene therapy/biotech, not conventional neural-interface hardware. The Adex snapshot's 2025 Series A participation under Albion should be reviewed against vehicle-level evidence; a portfolio-company milestone or continuing shareholding does not itself prove new-round participation. Individual Albion/fund contribution to the Series A was not found.
**Healios and Scripta** also appear in saved investments. Healios is a mental-health service/platform lead; Scripta is a neurodegenerative-disease drug-discovery lead. Neither was promoted to direct neurotechnology based on names or broad healthcare sector labels. Their detailed rounds/attribution need separate source review if used in Adex neurotech fields. No verified Albion BCI, implanted neural interface or neural-recording investment was found in the sources checked; that narrow absence does not negate verified ultrasound neuromodulation exposure.
## Conflicts, missing information and later Adex review
1. Review AUM: baseline approximately £1bn is dated historical evidence; official current headline is £1.2bn. Preserve currency, access date and manager scope. Third-party dollar-denominated AUM must not override official sterling.
2. Store live fundraising as **2026/27 VCT top-up target £40m plus optional £20m**, with £10.3m receipts as at 2026-10-06; do not store £60m as a closed single fund. Distinguish 2025/26 offer and the Crown-specific £30m close.
3. UCL Fund 2 £100m remains a **target** in the verified 2020 announcement. Current combined over £125m and older £122m figures do not determine a Fund 2 final close; obtain fund-level closing documentation if needed.
4. Add/review **NeuroHarmonics as Albion-managed UCL Technology Fund exposure** with unknown round/check and dated primary evidence. Preserve Neurofenix neurorehabilitation and EpilepsyGTx neuroscience-biotech classification boundaries.
5. Inspect snapshot participation `amount` fields that repeat total round size; the sources here establish syndicated financing totals, not Albion allocation. Also inspect duplicate TEM/Tem Energy entries and inconsistent stage/date labels rather than propagating them.
6. Exact check policy, current individual fund sizes/vintages, and exit dates for Neurofenix were not resolved. Current institutional strategies support a broader stage description than historical Series A-only claims. SHOW MORE
team@apexlogos.ai · 12 hours ago
Match research 2026-10-06 / AlbionVC / sha256:5de97f2c364fd0d6f74387944f7018ae437d57f124427069b83d084f231bf849 / part 1 of 3
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
# AlbionVC
- Exact Adex ID: `AlbionVC`
- Canonical Adex URL: https://adex.page/firms/AlbionVC
- Official website: https://albion.vc/
- Research date and access date for all sources: **2026-10-06**
- Status: **Complete research review; findings only, no Adex changes.**
## Summary and identity
AlbionVC is a London-based technology venture investor with retail VCT and institutional strategies. Its current official institutional page reports **£1.2 billion assets under management**, rather than a single £1.2 billion fund. The current mandate spans European pre-seed software/AI, pre-seed and seed deeptech/life sciences, and growth opportunities. Confirmed deeptech investments include IONATE, Oriole Networks and Phasecraft. **NeuroHarmonics is verified direct neurotechnology exposure through the Albion-managed UCL Technology Fund**; Neurofenix is device-enabled neurorehabilitation, and EpilepsyGTx is adjacent neuroscience gene therapy. [Official institutional strategies](https://albion.vc/institutional-investors/ ), [portfolio](https://albion.vc/companies/ ) (both undated, accessed 2026-10-06).
The saved record calls AlbionVC the technology investment arm of Albion Capital Group LLP, founded in 1996. Older official healthcare material uses that description. The current website footer instead identifies **AlbionVC LLP**, registration **OC341254**, as the FCA-regulated entity; current branding and historical manager names should be preserved with dates rather than silently treated as separate investors. [Healthcare primer](https://albion.vc/app/uploads/2022/07/HeathTech-Primer-2021.pdf ) (2021 material); [current philosophy and legal footer](https://albion.vc/our-philosophy/ ) (undated, accessed 2026-10-06).
## Starting evidence: saved Adex and NFX Signal
The exact-ID snapshot `data/research/_sources/AlbionVC.adex.json` was retrieved **2026-10-06T19:29:35.442Z** from read-only MCP Search. It contains one exact AlbionVC record, a description of approximately £1 billion venture assets, London location, source links to AlbionVC, NFX Signal and Goldi, and 90 investment-participation entries. Its firm-level minimum/maximum checks and sweet spot are null. Numerous investments have a round total repeated in the individual participation `amount` field; this is baseline data, not proof that Albion supplied the whole round. Relevant baseline names include Phasecraft, IONATE, Oriole, Bramble Energy, Neurofenix, EpilepsyGTx, Scripta and Healios. NeuroHarmonics was not among its listed investments.
The requested [NFX AlbionVC page](https://signal.nfx.com/firms/albionvc ) initially returned a substantial indexed/direct view, but repeated reads yielded only a short tracking-script shell; its firm-wide content could not be reliably recovered. A second [Signal page under “Albion VC”](https://signal.nfx.com/firms/albion-vc ) was directly readable and identifies London, Nadine Torbey and Robert Whitby-Smith, with Seed/Series A sector rankings including deeptech. It displays Nadine's $500,000–$5 million range/$4 million sweet spot and Robert's $5–10 million range/$7 million sweet spot. These are individual-profile claims, not verified firm check policies. [Jay Wilson's profile](https://signal.nfx.com/investors/jay-wilson ), directly/search-index accessible, likewise lists $5–10 million/$7 million and Seed/Series A rankings (undated, accessed 2026-10-06). Signal has duplicate firm spellings and intro-path sign-in gates; it is a discovery source, not independent confirmation of portfolio transactions or current fund size. No partner's previous-employer deals are attributed to Albion here.
## Capital, funds and current fundraising
| Capital measure / vehicle | Amount and status | Date and supporting source | Interpretation |
|---|---|---|---|
| AlbionVC manager AUM | **£1.2bn**, current website headline | [Institutional investors](https://albion.vc/institutional-investors/ ), undated, accessed 2026-10-06 | Manager assets, not an individual fund or available investment budget. No valuation/as-of date supplied. |
| Albion VCT assets | Website presents **780m AUM** in UK VCT context | [VCT overview](https://albion.vc/vct/ ), undated, accessed 2026-10-06 | VCT segment metric; the rendered headline omits the currency symbol. The UK context implies sterling, but review underlying reports before storing exact dated AUM. Another official Enterprise page still says over £680m, showing stale cross-page metrics. |
| Albion VCT **2026/27** top-up offers | **£40m base target plus possible £20m over-allotment**; **£10.3m raised as at 6 October 2026**, still open | [Official offers page](https://albion.vc/vct/offers/ ), explicitly dated 2026-10-06 | Latest-known live fundraising checked. Aggregate additions to three existing listed trusts, not a new standalone £60m VC fund or final close. Base allocations: Enterprise £15m, Crown £10m, Technology & General £15m; extra £10m each available for Enterprise/Technology & General subject to approval. |
| Albion VCT **2025/26** top-up offers | £60m base target plus £30m over-allotment; announced first-day receipts £11m | [Intention announcement](https://albion.vc/spotlight/news/intention-to-launch-albion-vct-top-up-offers-2/ ), 2025-08-27; [first-day update](https://albion.vc/spotlight/news/albions-vct-top-up-offer-raises-11mn-in-first-day/ ), 2025-11-05 | Historical offer, distinct from current 2026/27 campaign. |
| Albion Crown portion of 2025/26 offers | **£30m raised**; offer fully subscribed/closed 2026-03-16 | [Crown interim report](https://albion.capital/wp-content/uploads/2026/03/CRWN31Dec2025.pdf ), report to 2025-12-31 with later offer update | Crown's amount only. Do not multiply or assume an aggregate £90m final close without each trust's confirmation. |
| UCL Technology Fund 1 | **£50m** announced launch investment capital | [UCL launch notice](https://www.ucl.ac.uk/news/headlines/2016/jan/ucl-raises-ps50m-spin-new-companies-out-research ), 2016-01-18 | Research commercialisation vehicle, not all Albion assets. |
| UCL Technology Fund 2 | First close toward a **£100m target**; actual first-close amount not specified | [UCL Fund 2 announcement](https://www.ucl.ac.uk/news/2020/aug/ucl-technology-fund-announces-first-close-ps100m-fund-2 ), 2020-08-03 | Managed by AlbionVC with UCL Business. **£100m is a target**, not verified final-close capital. |
| UCL Technology Funds 1 + 2 combined | **Over £125m raised** | [UCL Ventures funding/support](https://www.uclventures.com/funding-support ), undated, accessed 2026-10-06 | Combined historical fundraising, not Fund 2 size. A 2025 prospectus stated £122m combined, likely a timing/scope difference requiring review. |
| Growth Opportunities Fund II | Current official page says investing from Fund II | [Institutional investors](https://albion.vc/institutional-investors/ ), undated, accessed 2026-10-06 | Size, vintage and final-close date not found in sources checked. Likewise no verified named current pre-seed/Frontiers fund close amount found. |
The [September 7, 2026 IFA Magazine headline](https://ifamagazine.com/albionvc-launches-60m-vct-top-up-offer-to-back-uks-next-tech-generation/ ) calls the new offer £60m. The official live page clarifies £40m base plus £20m optional capacity. The article was search-index accessible but direct opening returned 403; prefer the official split. The historical [2025/26 prospectus](https://albion.capital/wp-content/uploads/2025/10/Albion-VCTs-2025-2026-Securities-Note-23102025.pdf ), dated 2025-10-23, also reports over £700m VCT assets at 2025-06-30 and £122m combined UCL funds. These figures have different scopes and dates and should not replace one another without context.
## Investment stages and geography
Current explicit strategy is more varied than a Series A-only label: **pre-seed** European B2B software and AI-native first checks; **pre-seed to seed** research/IP-driven deeptech and life sciences through Frontiers; and **growth-stage** investment into established late-stage venture portfolio companies. [Official institutional page](https://albion.vc/institutional-investors/ ) (undated, accessed 2026-10-06). The broader philosophy says UK origins and investment across Europe. [Official philosophy](https://albion.vc/our-philosophy/ ) (undated, accessed 2026-10-06).
Historical Series A and Series B participation is independently evidenced below. The 2021 healthcare primer describes Series A as its core enterprise/healthcare focus; treat that as historical positioning, not a restriction on today's mandates. No definitive current firm-wide initial check range was verified.
## Named previous deeptech investments SHOW MORE
team@apexlogos.ai · 23 days ago
MATCH 
Atomico
TEM$75M · 2026-02-10
Tem Energy$75M · 2026-02-09
Koru Kids$12M · 2019-08-29
TransFICC$25M · 2025-04-09
OutThink$10M · 2022-10-18
Brytlyt$5M · 2021-12-22
IQ Capital
IONATE$17M · 2025-02-05
Speechmatics$62M · 2022-06-28
Concirrus$6M · 2020
Lightspeed
Oriole Networks£10M · 2024-03-27
Nozzle.ai$3M · 2020-11-18
Founders Fund
Kennek$13M · 2023-10-10
Plural
Phasecraft$34M · 2025-09-02
Labrys$— · 2025-06-03
Playground Global
Barbod Namini
Blue Lion Global
5mins$— · 2022-11-08
PeakData$12M · 2022-08-22
DFF Ventures
Digital Currency Group
Oviva$21M · 2020-01-14
Expeditions
Flok$12M · 2026
HV Capital
Ian Hogarth
Humanloop$2M · Unknown date
Patrick Norris
Treefera$30M · 2025-06-03
Peter Barrett
Planet A Ventures
Mondra$— · 2025-10-01
Portfolio Ventures
Project A Ventures
Root Ventures
XTX Ventures
